Stock Track | BAO PHARMA-B Plummets 6.39% Intraday as Market Skepticism Grows Over Buyback and Stake Increase Plans

Stock Track05-06

BAO PHARMA-B's stock plummeted 6.39% during intraday trading on Wednesday.

The decline reflects fading market enthusiasm for the company's previously announced supportive measures. Chairman Liu Yanjun had announced plans to increase his stake via open market transactions within three months, while the board proposed a share repurchase authorization of up to 10% of issued H shares. However, market participants have grown skeptical of actual execution: the repurchase remains an authorization rather than a binding commitment, and the company's cumulative losses of RMB 919 million over the past three years raise serious questions about available cash flow to fund meaningful buybacks.

The stock had previously suffered a dramatic flash crash triggered by profit-taking following weak annual results showing widening net losses. A brief rebound driven by the chairman's stake increase announcement has now fully reversed, as selling pressure from fundamental concerns overwhelms the short-term sentiment boost.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1196495000?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 10:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1196495000","market":"hk","top_or_hot":-1,"title":"Stock Track | BAO PHARMA-B Plummets 6.39% Intraday as Market Skepticism Grows Over Buyback and Stake Increase Plans","media":"Stock Track","content":"<p>BAO PHARMA-B's stock plummeted 6.39% during intraday trading on Wednesday.</p><p>The decline reflects fading market enthusiasm for the company's previously announced supportive measures. Chairman Liu Yanjun had announced plans to increase his stake via open market transactions within three months, while the board proposed a share repurchase authorization of up to 10% of issued H shares. However, market participants have grown skeptical of actual execution: the repurchase remains an authorization rather than a binding commitment, and the company's cumulative losses of RMB 919 million over the past three years raise serious questions about available cash flow to fund meaningful buybacks.</p><p>The stock had previously suffered a dramatic flash crash triggered by profit-taking following weak annual results showing widening net losses. A brief rebound driven by the chairman's stake increase announcement has now fully reversed, as selling pressure from fundamental concerns overwhelms the short-term sentiment boost.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BAO PHARMA-B Plummets 6.39% Intraday as Market Skepticism Grows Over Buyback and Stake Increase Plans</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BAO PHARMA-B Plummets 6.39% Intraday as Market Skepticism Grows Over Buyback and Stake Increase Plans\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-06 10:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BAO PHARMA-B's stock plummeted 6.39% during intraday trading on Wednesday.</p><p>The decline reflects fading market enthusiasm for the company's previously announced supportive measures. Chairman Liu Yanjun had announced plans to increase his stake via open market transactions within three months, while the board proposed a share repurchase authorization of up to 10% of issued H shares. However, market participants have grown skeptical of actual execution: the repurchase remains an authorization rather than a binding commitment, and the company's cumulative losses of RMB 919 million over the past three years raise serious questions about available cash flow to fund meaningful buybacks.</p><p>The stock had previously suffered a dramatic flash crash triggered by profit-taking following weak annual results showing widening net losses. A brief rebound driven by the chairman's stake increase announcement has now fully reversed, as selling pressure from fundamental concerns overwhelms the short-term sentiment boost.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02659","symbol_name":"宝济药业-B","start_time":0,"source_url":"","article_id":"1196495000","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1196495000","pubTimestamp":1778035975,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"BAO PHARMA-B's stock plummeted 6.39% during intraday trading on Wednesday.The decline reflects fading market enthusiasm for the company's previously announced supportive measures. Chairman Liu Yanjun...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02659":"宝济药业-B"},"translate_title":"个股追踪|宝药业-B盘中暴跌6.39%市场对回购增持计划质疑加剧","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02659":1},"content_text":"BAO PHARMA-B's stock plummeted 6.39% during intraday trading on Wednesday.The decline reflects fading market enthusiasm for the company's previously announced supportive measures. Chairman Liu Yanjun had announced plans to increase his stake via open market transactions within three months, while the board proposed a share repurchase authorization of up to 10% of issued H shares. However, market participants have grown skeptical of actual execution: the repurchase remains an authorization rather than a binding commitment, and the company's cumulative losses of RMB 919 million over the past three years raise serious questions about available cash flow to fund meaningful buybacks.The stock had previously suffered a dramatic flash crash triggered by profit-taking following weak annual results showing widening net losses. A brief rebound driven by the chairman's stake increase announcement has now fully reversed, as selling pressure from fundamental concerns overwhelms the short-term sentiment boost.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1196495000","isCrawlerRequest":true}